Rathbone M P, Middlemiss P J, Gysbers J W, Andrew C, Herman M A, Reed J K, Ciccarelli R, Di Iorio P, Caciagli F
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Prog Neurobiol. 1999 Dec;59(6):663-90. doi: 10.1016/s0301-0082(99)00017-9.
In addition to their well known roles within cells, purine nucleotides such as adenosine 5' triphosphate (ATP) and guanosine 5' triphosphate (GTP), nucleosides such as adenosine and guanosine and bases, such as adenine and guanine and their metabolic products xanthine and hypoxanthine are released into the extracellular space where they act as intercellular signaling molecules. In the nervous system they mediate both immediate effects, such as neurotransmission, and trophic effects which induce changes in cell metabolism, structure and function and therefore have a longer time course. Some trophic effects of purines are mediated via purinergic cell surface receptors, whereas others require uptake of purines by the target cells. Purine nucleosides and nucleotides, especially guanosine, ATP and GTP stimulate incorporation of [3H]thymidine into DNA of astrocytes and microglia and concomitant mitosis in vitro. High concentrations of adenosine also induce apoptosis, through both activation of cell-surface A3 receptors and through a mechanism requiring uptake into the cells. Extracellular purines also stimulate the synthesis and release of protein trophic factors by astrocytes, including bFGF (basic fibroblast growth factor), nerve growth factor (NGF), neurotrophin-3, ciliary neurotrophic factor and S-100beta protein. In vivo infusion into brain of adenosine analogs stimulates reactive gliosis. Purine nucleosides and nucleotides also stimulate the differentiation and process outgrowth from various neurons including primary cultures of hippocampal neurons and pheochromocytoma cells. A tonic release of ATP from neurons, its hydrolysis by ecto-nucleotidases and subsequent re-uptake by axons appears crucial for normal axonal growth. Guanosine and GTP, through apparently different mechanisms, are also potent stimulators of axonal growth in vitro. In vivo the extracellular concentration of purines depends on a balance between the release of purines from cells and their re-uptake and extracellular metabolism. Purine nucleosides and nucleotides are released from neurons by exocytosis and from both neurons and glia by non-exocytotic mechanisms. Nucleosides are principally released through the equilibratory nucleoside transmembrane transporters whereas nucleotides may be transported through the ATP binding cassette family of proteins, including the multidrug resistance protein. The extracellular purine nucleotides are rapidly metabolized by ectonucleotidases. Adenosine is deaminated by adenosine deaminase (ADA) and guanosine is converted to guanine and deaminated by guanase. Nucleosides are also removed from the extracellular space into neurons and glia by transporter systems. Large quantities of purines, particularly guanosine and, to a lesser extent adenosine, are released extracellularly following ischemia or trauma. Thus purines are likely to exert trophic effects in vivo following trauma. The extracellular purine nucleotide GTP enhances the tonic release of adenine nucleotides, whereas the nucleoside guanosine stimulates tonic release of adenosine and its metabolic products. The trophic effects of guanosine and GTP may depend on this process. Guanosine is likely to be an important trophic effector in vivo because high concentrations remain extracellularly for up to a week after focal brain injury. Purine derivatives are now in clinical trials in humans as memory-enhancing agents in Alzheimer's disease. Two of these, propentofylline and AIT-082, are trophic effectors in animals, increasing production of neurotrophic factors in brain and spinal cord. Likely more clinical uses for purine derivatives will be found; purines interact at the level of signal-transduction pathways with other transmitters, for example, glutamate. They can beneficially modify the actions of these other transmitters.
除了在细胞内发挥众所周知的作用外,嘌呤核苷酸如腺苷5'-三磷酸(ATP)和鸟苷5'-三磷酸(GTP)、核苷如腺苷和鸟苷以及碱基如腺嘌呤和鸟嘌呤及其代谢产物黄嘌呤和次黄嘌呤会释放到细胞外空间,在那里它们作为细胞间信号分子发挥作用。在神经系统中,它们介导即时效应,如神经传递,以及诱导细胞代谢、结构和功能发生变化的营养效应,因此具有较长的时间进程。嘌呤的一些营养效应是通过嘌呤能细胞表面受体介导的,而其他效应则需要靶细胞摄取嘌呤。嘌呤核苷和核苷酸,尤其是鸟苷、ATP和GTP,在体外刺激星形胶质细胞和小胶质细胞将[3H]胸苷掺入DNA并伴随有丝分裂。高浓度的腺苷还通过激活细胞表面A3受体以及通过一种需要摄取到细胞内的机制诱导细胞凋亡。细胞外嘌呤还刺激星形胶质细胞合成和释放蛋白质营养因子,包括碱性成纤维细胞生长因子(bFGF)、神经生长因子(NGF)、神经营养因子-3、睫状神经营养因子和S-100β蛋白。在体内向脑内注入腺苷类似物会刺激反应性胶质增生。嘌呤核苷和核苷酸还刺激包括海马神经元原代培养物和嗜铬细胞瘤细胞在内的各种神经元的分化和突起生长。神经元持续释放ATP,其被胞外核苷酸酶水解,随后被轴突重新摄取,这对正常轴突生长似乎至关重要。鸟苷和GTP通过明显不同的机制,也是体外轴突生长的有效刺激剂。在体内,嘌呤的细胞外浓度取决于细胞释放嘌呤与其重新摄取和细胞外代谢之间的平衡。嘌呤核苷和核苷酸通过胞吐作用从神经元释放,通过非胞吐机制从神经元和胶质细胞释放。核苷主要通过平衡型核苷跨膜转运体释放,而核苷酸可能通过ATP结合盒蛋白家族转运,包括多药耐药蛋白。细胞外嘌呤核苷酸被胞外核苷酸酶迅速代谢。腺苷被腺苷脱氨酶(ADA)脱氨,鸟苷转化为鸟嘌呤并被鸟苷酶脱氨。核苷也通过转运系统从细胞外空间被摄取到神经元和胶质细胞中。在缺血或创伤后,大量嘌呤,特别是鸟苷,以及程度较轻的腺苷会释放到细胞外。因此,嘌呤可能在创伤后在体内发挥营养作用。细胞外嘌呤核苷酸GTP增强腺嘌呤核苷酸的持续释放,而核苷鸟苷刺激腺苷及其代谢产物的持续释放。鸟苷和GTP的营养效应可能取决于这个过程。鸟苷可能是体内一种重要的营养效应物,因为在局灶性脑损伤后,高浓度的鸟苷在细胞外可保持长达一周。嘌呤衍生物目前正在人体临床试验中作为阿尔茨海默病的记忆增强剂。其中两种,丙戊茶碱和AIT-082,在动物中是营养效应物,可增加脑和脊髓中神经营养因子的产生。可能会发现嘌呤衍生物有更多的临床用途;嘌呤在信号转导途径水平与其他递质相互作用,例如谷氨酸。它们可以有益地改变这些其他递质的作用。